In late 2002, the firm was delisted form OTC and declared bankruptcy. Nexell Therapeutics had been biopharmaceutical company developing products utilizing cell separation technology in cell therapy for cancer and other life-threatening diseases. Following the bankruptcy, Nexell Therapeutics transferred back to Baxter Healthcare worldwide licensing rights to its cell processing products that had been at the heart of the firm's operations Principal sof the firm then sold the company certain assets and liabilities of its cell processing business, plus all of the stock of its wholly owned subsidiary, Nexell International SPRL for $4.3mm plus royalties. The firm appears in May 2016 to have returned to the active mode with announcement on Crunchbase of an $850K investment.
